Morgan Stanley Sellas Life Sciences Group, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Morgan Stanley holds 17,435 shares of SLS stock, worth $20,747. This represents 0.0% of its overall portfolio holdings.
Number of Shares
17,435
Previous 3,297
428.81%
Holding current value
$20,747
Previous $3,000
600.0%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SLS
# of Institutions
39Shares Held
5.69MCall Options Held
1.67MPut Options Held
74.7K-
Vanguard Group Inc Valley Forge, PA2.29MShares$2.73 Million0.0% of portfolio
-
Anson Funds Management LP Dallas, TX794KShares$944,6630.12% of portfolio
-
Geode Capital Management, LLC Boston, MA605KShares$720,1770.0% of portfolio
-
Black Rock Inc. New York, NY430KShares$512,1370.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$367,0743.71% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $24.5M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...